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Abstract 
D-Glucuronate and L-iduronate-containing disaccharides related to the antithrombin-binding 
domain of heparin were prepared. The carboxylic function of the uronic acid unit was formed 
on a disaccharide level in the case of the glucuronate, while on a monosaccharide level in the 
case of the iduronate derivatives. Synthesis of their sulfonic acid analogues was carried out 
analoguosly applying sulfonatomethyl-containing acceptors in form of either salts or methyl 
esters. Significant difference could be observed in the methyl ether formation reactions of the 
sulfonatomethyl-containing uronate disaccharides and the non-sulfonic acid uronates. 
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1. Introduction 
 Heparin, a highly sulfated linear polysaccharide belonging to the family of 
glycosaminoglycans is a well-known blood anticoagulant employed extensively in medical 
practice.1 The anticoagulant action of heparin arises from its ability to accelerate the 
inhibitory activity of antithrombin III (AT-III), a serine protease inhibitor that blocks 
thrombin and factor Xa in the blood-coagulation cascade.2 After identification of the exact 
sequence of heparin that associates with the AT-III (1) a concerted drug development program 
has been undertaken based on extensive structure-activity studies using synthetic 
oligosaccharides.3 These efforts resulted in fondaparinux (2), a synthetic pentasaccharide 
heparin analogue which is used as a new antithrombotic drug under the name Arixtra.4 
Fondaparinux selectively inhibits factor Xa, and it has longer half-life and higher anti-Xa 
activity than heparin and low molecular-weight heparin. However, its synthesis represents a 
real challenge, due to the presence of D-glucuronic acid, L-iduronic acid and α-D-
glucosamine, most of them N- and O-sulfated on selected positions. Based on the observations 
of SAR studies that the N-sulfate groups could be replaced by O-sulfates, and the free 
hydroxyl groups could be masked with alkyl groups, a family of non-glycosaminoglycan 
derivatives was created,5 having simplified structures much easier to synthesize than 
fondaparinux. In addition, idraparinux5,6 (3a), the most potent representative of these 
analogues possesses increased anticoagulant activity and longer duration of action (Figure 
1).4a,5 It turned out, however, that the extremly long elimination half-life of idraparinux (~ 60 
days by clinical trials) may lead to serious bleeding complications, therefore its development 
  
was terminated.7 Idrabiotaparinux (3b), the biotinylated form of 3a has been developed with 
the aim to improve the management of bleeding events seen with idraparinux.8 
Idrabiotaparinux displays the same advantageous properties as idraparinux and has the added 
safety feature of easy and rapid neutralization of its anticoagulant effect by addition of the 
specific antidote, avidin.7,8  
 
Figure 1. Structures of the antithrombin-binding domain of heparin (1), synthetic 
antithrombotic drug fondaparinux (2), the non-glycosaminoglycan analogue idraparinux (3a) 
and its biotinylated derivative idrabiotaparinux (3b). 
 
Our research group decided the synthesis of the isosteric sulfonic acid analogues of 
idraparinux (2) by systematic replacement of the sulfate esters with sulfonatomethyl moieties 
to obtain new selective Xa inhibitors and to acquire further information on the structure-
activity relationship of the antithrombotic action of heparin pentasaccharide. It is known that 
the anionic groups are essential for the activation of AT-III, and that the type of charge is also 
crucial,3c however, replacement of the sulfate group with sulfonic acid moiety has not been 
investigated till now. 
Synthesis of sulfonatomethyl analogues of the EF and GH disaccharides (5-7 and 9-11) 9 as 
well as sulfonatomethyl analogues10 of the DEF trisaccharide of compound 3a have been 
reported recently. Here, we present the synthesis of two uronic acid-containing fragments of 
idraparinux (4 and 8) together with unpublished details of the synthesis of their sulfonic acid 
mimetics (Figure 2). Differences in the synthesis of disaccharide uronates with or without 
sulfonic acid content are also discussed.  
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Figure 2. Structures of the EF and the GH fragments of idraparinux (4 and 8) and their 
isosteric sulfonic acid derivatives (5-7 and 9-11). 
 
2. Results and discussion 
 
 For the synthesis of compound 4 the β-(1-4)-linked skeleton was prepared by coupling of 
donor 1211 and acceptor 1312 and the disaccharide 14 was isolated in high yield. Zemplén 
deacetylation of 14  afforded the tetrahydroxy derivative 15. Selective oxidation of the 
primary hydroxyl group of compound 15 by TEMPO-based oxidation method13 using 
sodium-hypochlorite as co-oxidant gave compound 16. Treatment of 16 with methyl iodide 
and sodium hydride to achieve methylation of the three hydroxyl groups of the uronic acid 
residue resulted in a 3:2 mixture of the desired product 17 and the by-product 18 formed by β-
elimination. Catalytic hydrogenation of 17 afforded the triol 19 which was O-sulfated to 
obtain the target disaccharide 4 (Scheme 1). 
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Scheme 1. Synthesis of the EF fragment of idraparinux by selective oxidation. Reagents and 
conditions: (a) CH2Cl2-toluene, 4 Å Ms, AgOTf, -30 oC to rt, 24 h (94%); (b) MeOH, NaOMe, 
rt, 2 h (97%); (c) sat NaHCO3, KBr, NaOCl, TEMPO, 0 oC to rt, 2 h (78%); (d) DMF, NaH, 
MeI, 0 oC to rt, 2 h (17: 42%, 18: 40%); (e) ethanol, Pd(C), H2, 10 atm, rt, 12 h (94%); (f) 
DMF, SO3·py, 0 oC to rt, 5 h (70%). 
 
In order to avoid the elimination side reaction caused by methylation of the base-sensitive 
uronate derivative, compound 17 was prepared from 15 by permuting the oxidation and 
methylation steps. The primary hydroxyl of 15 was protected temporarily in form of trityl 
ether, then the secondary hydroxyls of 20 were methylated to afford 21. Removal of the trityl 
group gave 22 whose TEMPO-based oxidation resulted in the fully protected glucuronide 17 
in good yield (Scheme 2). Synthesis of 4 starting from 12 and 13 through the 6-O-trityl 
intermediate 20 required eight steps and resulted in the target glucuronide disaccharide with 
27% overall yield. 
 
 
 
Scheme 2. Improved synthesis of the methylated uronate 17. Reagents and conditions: (a) py, 
TrCl, 0 oC to rt, 24 h (83%); (b) DMF, NaH, MeI, 0 oC to rt, 2 h (86%); (c) 80% AcOH, 50 oC, 
2 h (98%); (d) sat NaHCO3, KBr, NaOCl, TEMPO, 0 oC to rt, 2 h (64%). 
 
To obtain the sulfonic acid analogues of disaccharide 4, first the sulfonatomethyl-containing 
glucoside acceptors have to be prepared.9 The key step of their synthesis was the addition of 
hydrogen sulfite to the exomethylene moiety of the appropriate glucoside resulting 
exclusively in the primary alkane sulfonate in a radical chain reaction using tert-butyl 
peroxybenzoate as radical initiator.14,15  
Previously, the 2-deoxy-2-sulfonatomethyl and the 3-deoxy-3-sulfonatomethyl acceptors (24 
and 27) have been prepared by the following sequence of reactions: the exomethylene 
  
derivatives 2316 and 26,17 were reacted with NaHSO3, respectively, followed by regioselective 
hydrogenolysis of the 4,6-O-benzylidene acetal. However, the 4-OH derivatives 24 and 27 
could be isolated only with moderate yields due to partial hydrolysis of the benzylidene acetal 
under the slightly acidic conditions of the first addition step.9 We attempted to increase the 
yield of the two-step procedure by reversing the acetal reduction and the addition. In the case 
of the 3-exomethylene derivative 26 regioselective opening of the 4,6-O-acetal ring using a 
triethylsilane-BF3·Et2O reagent combination18 (28), and subsequent sulfonation afforded the 
desired 27 with increased yield compared to the previous pathway (65% versus 47% over 2 
steps). However, treatment of 23 with Et3SiH/BF3·Et2O resulted in the unexpected 2-methyl 
glycal 25 as the main product. The reaction can be explained by formation of a stabilized 
allylic cation (allyl oxocarbenium ion) whose reaction with the hydride donor reagent gave 
the 2-deoxy-2-methyl glycal derivative (Scheme 3). 
Cleavage of the glycosidic bond upon reductive opening of benzylidene-type acetals is 
extremely rare, however, not unprecedented.19,20  
 
 
 
 
Scheme 3. Previously described  (a followed by b) and recent (b followed by a) reaction 
routes for the 2-deoxy-2-sulfonatomethyl and the 3-deoxy-3-sulfonatomethyl acceptors. 
Reagents and conditions: (a) 70% EtOH, tBu-peroxybenzoate, NaHSO3, reflux, 4 h (55% 
from 23, 53% from 26, 74% from 28); (b) CH2Cl2, Et3SiH, BF3·Et2O, 0 oC to rt, 4 h (24: 87%, 
27: 88%, 25: 41%, 28: 78%).  
 
 
The 2-(sodium sulfonatomethyl)- and 3-(sodium sulfonatomethyl)-containing analogues of 
disaccharide 4 have been synthesized through the appropriate 6’-O-trityl intermediates, 
starting from the acetobromo glucose 12 and acceptors 24 and 27, respectively, as we 
published recently.9 (It is worth to mention that the sulfonic acid salts proved to be excellent 
acceptors, and similar overall yields could be achieved for the sulfonic acid-containing 
disaccharides 5 and 6 as for compound 4.)  
However, preparation of the 6-(sodium sulfonatomethyl)-containing derivatives 7 via 
tritylation was failed. Glycosylation of the sulfonic acid heptoside 299 in a salt form with the 
acetobromo glucose donor 12 upon silver triflate activation and the following deacetylation 
took place smoothly affording the desired disaccharide 30 in a 48% yield.9 However, 
subsequent tritylation of 30 failed, despite a high excess of the reagent, addition of 
dimethylamino pyridine and prolongation of the reaction time (Scheme 4). Silylation using 
tert-butyldiphenylsilyl chloride was also unsuccessful.  
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Scheme 4. Attempted synthesis of the 6-deoxy-6-sulfonatomethyl analogue of the EF 
fragment of idraparinux via tritylation. Reagents and conditions: (a) CH2Cl2-toluene, 4 Å Ms, 
AgOTf, -30 oC to rt, 24 h (64%); (b) MeOH, NaOMe, rt, 2 h (75%); (c) TrCl (3 equiv), py, 
DMAP (d) TBDPSCl, imidazole, DMF. 
 
Geometry optimization on the structures sampling from high temperature molecular dynamics 
simulations trajectory for 30 gave explanation for the failure of substitution of the 6’-hydroxyl 
group. In the lowest energy conformations the hydroxyl group is inaccessible by the bulky 
reagents being in a pocket formed by the two benzyl groups and the sugar ring (Figure 3). 
These conformations are probably stabilized by hydrogen bonds between the sulfonate moiety 
and the 2’- or 3’-hydroxyls. (For the most stable geometry the corresponding distances 
between the sulfonate oxygens and the 2’- or 3’-hydroxyl hydrogens are 1.84 Å for 2’-OH 
and 1.91 Å for 3’-OH from DFT calculations while 1.77 Å for 2’-OH and 1.64 Å for 3’-OH 
were predicted by the AMBER-GAFF force field.) The above assumptions were confirmed by 
NMR experiments: the hydrogen of the 6’-OH could be exchanged for deuterium 
immediately, while deuteration of 2’-OH and 3’-OH was slow. 
 
  
 
Figure 3. Superposition of the six lowest energy conformations of 30 from the high 
temperature molecular dynamics (ball-and-stick representation: lowest energy conformer; 
stick representation: conformers 2-6) 
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Scheme 5. Synthesis of the 6-deoxy-6-sulfonatomethyl analogue of the EF fragment of 
idraparinux by selective oxidation. Reagents and conditions: (a) sat NaHCO3, KBr, NaOCl, 
TEMPO, 0 oC to rt, 2 h (91%); (b) DMF, NaH, MeI, 0 oC to rt, 2 h (79%); (c) ethanol, Pd(C), 
H2, 10 atm, rt, 12 h (96%); (d) DMF, SO3·py, 0 oC to rt, 5 h (65%). 
 
Since selective protection of the sterically hindered 6’-hydroxyl group failed, the tetrahydroxy 
derivative 30 was converted directly into the uronic acid 31 by TEMPO-based selective 
oxidation. Methylation of 31 with methyl iodide and sodium hydride was considered to be a 
risky step that might lead to β-elimination of the uronic acid residue as it happened to 16. 
Surprisingly, methylation in the presence of the stronge base proceeded smoothly and no 
  
elimination was observed (Scheme 5). The obtained 32 could be converted into the targeted 6-
deoxy-6-sulfonatomethyl-containing disaccharide 7 by catalytic hydrogenation and 
subsequent sulfation of the liberated two hydroxyls. Applying the selective oxidation method 
a 22% overall yield could be obtained for 7 in a 6-step procedure.9  
 
For the incorporation of uronic acid residues into oligosaccharides two distinct strategies 
exist: glycosylation followed by oxidation (post-glycosidation oxidation) and oxidation of the 
monosaccharide building blocks followed by glycosylation (pre-glycosidation oxidation).21 
Although the glucuronide-containing disaccharides were prepared succesfully by post-
glycosidation oxidation, the other strategy, that is glycosylation with an iduronic donor was 
selected to synthesize our targeted GH analogue disaccharides 8-11.  Since neither idose nor 
iduronic acid are readily available from natural and commercial sources and preparation of 
both type of donors requires a lengthy synthetic procedure,22 the pre-glycosidation oxidation 
seemed to be more efficient. 
L-Iduronic acid trichloroacetimidate 39 was prepared on the basis of the well-established 
procedure elaborated for the appropriate 3-O-benzyl-L-iduronate donor.22h,23 The iduronic 
acid 36 was prepared from the corresponding D-glucofuranuronic acid derivative24 by means 
of a two-step epimerization at C-5.23 Deisopropylidenation of 36 with trifluoroacetic acid 
afforded  the desired hemiacetal as a mixture of pyranoses and furanoses. Acetylation of the 
crude reaction mixture, followed by column chromatography gave 37 with 36% yield over the 
two steps. Selective deacetylation of the anomeric position (38) and imidate formation then 
resulted in the iduronic acid donor 39 (Scheme 6). 
 
 
 
Scheme 6. Synthesis of the L-iduronate donor. Reagents and conditions: (a) 90% F3CCOOH, 
rt, 15 min; (b) py, Ac2O, 0 oC to rt, 24 h (36% for 2 steps); (c) THF, BnNH2, rt, 3 h (79%); (d) 
CH2Cl2, DBU, trichloroacetonitrile, 0 oC, 30 min (72%).  
 
Coupling of the acceptor 13 with the imidate donor 39 upon trimethylsilyl triflate activation 
afforded the disaccharide 40 and its Zemplén deacetylation resulted in diol 41. Attempted 
methylation with methyl iodide and sodium hydride failed leading to complete β-elimination 
of the iduronic acid residue, therefore, the strong base was exchanged into freshly prepared 
silver(I)oxide. Under such conditions the methylated 42 was obtained in high yield and no 
elimination occurred. The uronic ester was treated with aqueous sodium hydroxide to give the 
sodium uronate 43.  Removal of the benzyl protecting groups by catalytic hydrogenation 
resulted in the triol 44 which upon sulfation with the SO3·pyridine complex furnished the GH 
fragment of idraparinux (8, Scheme 7). Overall yield for 8 was 37% starting from 39 and 13. 
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Scheme 7. Synthesis of the GH fragment of idraparinux. Reagents and conditions: (a) 
CH2Cl2, 4 Å Ms, TMSOTf, -20 oC, 30 min (94%); (b) MeOH, NaOMe, rt, 1 h (95%); (c) 
DMF, Ag2O, MeI, rt, 96 h (76%); (d) 0.1 M NaOH, rt, 24 h (68%); (e) ethanol, Pd(C), H2, rt, 
12 h (85%); (f) DMF, SO3·py, 0 oC to rt, 5 h (94%). 
 
Coupling of the sulfonatomethyl glucosides in salt form (24, 27 and 29) with the iduronic acid 
donor failed, therefore, the sulfonic acids in form of the methyl esters were resorted as the 
acceptors. The methyl ester 45 was prepared from the salt 24 by liberation of the sulfonic acid 
followed by esterification with ethereal diazomethane.9 Glycosylation of the 2-deoxy-2-
sulfonatomethyl glucoside acceptor 45 with the donor 39 afforded the desired α-linked 
disaccharide whose deacetylation gave 46 in a high yield. Usual methylation was attempted 
applying sodium hydride and methyl iodide, since similar methylation of the sulfonic acid-
containing glucuronate 31 took place smoothly. However, with 46 an inseparable mixture of 
the desired product 47 and the by-product 48 (as a result of β-elimination of the base-sensitive 
iduronic acid residue) was formed in a ratio of ~3:1. To overcome this difficulty, methylation 
of 46 was carried out under slightly acidic conditions with diazomethane25 applying silica 
gel25b or BF3·Et2O25c to catalyze the reaction. The silica gel promoted methylation proved to 
be more efficient affording the desired product 4949 in high yield. Compound 49, carrying two 
ester functions, was converted into the disodium salt in two steps; the sulfonic ester was 
treated with sodium iodide in acetone to give the sodium sulfonate in a nucleophilic 
substitution reaction, then the crude product was reacted with aqueous sodium hydroxide in 
methanol to hydrolyze the carboxylic ester giving sodium uronate. Catalytic hydrogenation 
and subsequent sulfation afforded the 2-deoxy-2-sulfonatomethyl-containing disaccharide 9 
with 55% overall yield over 8 steps (Scheme 8).9 
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Scheme 8. Synthesis of the 2-deoxy-2-sulfonatomethyl analogue of the GH fragment of 
idraparinux. Reagents and conditions: (a) 39, CH2Cl2, 4 Å Ms, TMSOTf, -20 to 0 oC, 15 min 
(80%); (b) MeOH, NaOMe, rt, 2 h (97%); (c) DMF, NaH, MeI (d) CH2Cl2, CH2N2, silicagel, 
0 oC (88%); (e) acetone, NaI, rt, 2 h; (f) 0.1 M NaOH, rt, 24 h (96% over two steps); (g) 
ethanol, Pd(C), H2, 10 atm, rt, 12 h (97%); (h) DMF, SO3·py, 0 oC to rt, 5 h (87%). 
 
 
The synthesis of  the 3-sulfonatomethyl- and the 6-sulfonatomethyl-containing iduronides 10 
and 11 has been published in detail.9 Their preparation was carried out analogously to 
compound 9, except for the  the methylation step. It is important to note, that methylation of 
diols 50 and 51 using sodium hydride and methyl iodide did not cause elimination side 
reaction and afforded exclusively the desired products 52 and 53, respectively (Scheme 9). In 
the end 42% overall yield could be achieved for 10 and 48% for 11 starting from the iduronic 
acid donor and the methyl sulfonatomethyl-containing acceptors. 
 
 
 
 
Scheme 9. Synthesis of the 3-deoxy-3-sulfonatomethyl and 6-deoxy-6-sulfonatomethyl  
analogues of compound 8.  
 
   
  
In conclusion, the EF and GH disaccharide fragments of idraparinux were prepared following 
two different strategies. The glucuronic acid containing EF disaccharide was synthesized by 
post-glycosidation oxidation using an acetobromo glucose donor to build up the disaccharide 
skeleton and TEMPO-based oxidation to form the carboxylic function at a disaccharide level. 
Preparation of the iduronic acid- containing GH disaccharide was carried out by pre-
glycosidation oxidation using an iduronic acid donor to achieve the disaccharide uronate.  
Synthesis of the sulfonic acid analogues could be carried out analoguosly applying 
sulfonatomethyl-containing acceptors in form of salts and methyl esters. The sulfonatomethyl 
glucosides in the form of salts were efficient acceptors when reacting with the acetobromo 
glucose donor. The glycosylation reactions failed when the sulfonic acid salt acceptors were 
reacted with the iduronic acid donor with inherently low reactivity. In that case the sulfonic 
acid acceptors in form of esters were applied to effectuate the glycosylations in high yields. 
Comparing the efficacy of the synthesis of disaccharides with or without sulfonic acid content 
similar overall yields could be reached for the non-sulfonic acid disaccharides (4 and 8) and 
their sulfonatomethyl-containing analogues (5-7 and 9-11). 
Interestingly, the sulfonatomethyl-containing uronate disaccharides proved to be significantly 
more stable under the basic conditions of methylation than the non-sulfonic acid uronates. 
There was only one precedent for β-elimination of the base-sensitive uronates of the sulfonic 
acid analogues (namely, the reaction of 46 with sodium hydride and methyl iodide). In that 
case, methylation was carried out under acidic conditions applying ethereal diazomethane in 
the presence of silica gel. 
Synthesis of the pentasaccharide analogues of idraparinux by applying the presented methods, 
as well as biological investigations of the prepared sulfonic acid derivatives are in progress. 
 
3. Experimental 
 
3.1. General Information 
Optical rotations were measured at room temperature with a Perkin-Elmer 241 automatic 
polarimeter. TLC was performed on Kieselgel 60 F254 (Merck) with detection by immersing 
into 5% ethanolic sulfuric acid soln. followed by heating. Column chromatography was 
performed on Silica gel 60 (Merck 0.063-0.200 mm) and Sephadex LH-20 (Sigma-Aldrich, 
Bead size 25-100 µ). Organic solutions were dried over MgSO4, and concentrated in vacuum. 
The 1H (200, 360, 400 and 500 MHz) and 13C NMR (50.3, 90.54, 100.28, 125.76 MHz) 
spectra were recorded with Bruker AC-200, Bruker DRX-360, Bruker DRX-400 and Bruker 
DRX-500 spectrometers. Chemical shifts are referenced to Me4Si (0.00 ppm for 1H) or to the 
residual solvent signals (CDCl3: 77.00 ppm for 13C). 
MALDI-TOF MS analyses of the compounds were carried out in the positive reflectron mode 
using a BIFLEX III mass spectrometer (Bruker, Germany) equipped with delayed-ion 
extraction. The matrix solution was a satd 2,4,6-trihydroxy-acetophenone (THAP) solution in 
MeCN. 
The molecular dynamics simulations (100 ns, 1200 K constant temperature, 1 fs time step) 
and the preliminary geometry optimizations using the suitably developed GAFF empirical 
force field on the equidistantly saved 100,000 trajectory snapshot geometries were carried out 
by means of the AMBER molecular dynamics simulation package.26,20 The B3LYP/6-31G(d) 
density functional calculation on the lowest energy conformer was carried out using the 
GAUSSIAN 03 package.27 Ball-and-stick and stick representations of the conformers were 
generated by the VMD software.28 
 
 
 
  
3.2. Methyl (2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-α-D-
glucopyranoside (14) 
To a mixture of compound 13 (1.00 g, 2.16 mmol) and acetobromoglucose (12, (1.78 g, 4.32 
mmol) ) in dry CH2Cl2 (20 mL) powdered 4 Å molecular sieves (1.5 g) was added. The stirred 
mixture was cooled to 0 oC under argon. After 1 h at this temperature, AgOTf (1.2 g, 4.68 
mmol) dissolved in toluene (4 mL) was added. After another hour the reaction was allowed to 
warm up to room temperature and stirred overnight. The reaction mixture was filtered through 
a pad of Celite. After filtration Et3N (1 mL) was added, and the solvents were evaporated in 
vacuo. The crude product was purified by silica gel chromatography (1:1 n-hexane-EtOAc) to 
give 14 (1.61 g, 94%) as a colourless syrup. [α]D -6.2 (c 0.11, CHCl3); Rf 0.42 (1:1 n-hexane-
EtOAc); 1H NMR (CDCl3, 360 MHz): δ (ppm) 7.38-7.27 (m, 15H, arom.), 5.01-4.39 (m, 
10H), 4.15 (m, 1H), 3.91-3.35 (m, 9H), 3.37 (s, 3H, OCH3), 2.00, 1.98, 1.95 (3 x s, 12H, 4 x 
CH3); 13C NMR (CDCl3, 90 MHz): δ (ppm) 170.4, 170.0, 169.2, 168.8 (4C, 4 x CO), 139.2, 
138.1, 137.5 (3C, 3 x Cq arom.), 128.5-127.0 (arom.), 99.8, 98.2 (C-1, C-1’), 79.7, 78.7, 77.1, 
73.0, 71.7, 71.3, 69.5, 67.9 (skeleton carbons), 74.9, 73.5, 73.3 (3 x PhCH2), 67.4 (C-6’), 61.5 
(C-6), 55.2 (OCH3), 20.5, 20.4, 20.3 (4 x CH3); MALDI-TOF (positive ion): m/z 817.17  
[M+Na]+ (Calcd 817.30). Anal. Calcd for C42H50O15 (794.84): C, 63.47; H, 6.34. Found: C, 
63.33; H, 6.29. 
 
3.3. Methyl (β-D-glucopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside (15) 
To a solution of 14 (1.45 g, 1.82 mmol) in MeOH (25 mL) catalytic amount of NaOMe (11 
mg, 0.2 mmol) was added. After 2 h stirring, the mixture was neutralized with Amberlite IR-
120 H+ ion-exchange resin, filtered, and concentrated to give 15 (1.11 g, 97%) as a colourless 
syrup. [α]D +5.4 (c 0.19, MeOH); Rf 0.42 (9:1 CH2Cl2-MeOH); 1H NMR (CD3OD, 360 
MHz): δ (ppm) 7.44-7.26 (m, 15H, arom.), 4.96 (d, 1H, J 10.3 Hz, PhCH2), 4.76 (d, 1H, J1,2 
3.6 Hz, H-1), 4.70-4.51 (m, 5H, PhCH2), 4.41 (d, 1H, J1’,2’ 7.3 Hz, H-1’), 4.00-3.95 (m, 2H), 
3.86-3.69 (m, 4H), 3.55-3.46 (m, 2H), 3.37 (s, 3H, OCH3), 3.30-3.17 (m, 4H); 13C NMR 
(CD3OD, 90 MHz): δ (ppm) 139.5 (3 x Cq arom.), 129.9-128.7 (arom.), 103.5 (C-1’), 99.0 (C-
1), 81.6, 80.6, 78.8, 77.9, 76.5, 75.7, 72.1, 71.6 (skeleton carbons), 77.3, 74.2, 74.1 (3 x 
PhCH2), 69.2 (C-6), 63.3 (C-6’), 55.6 (OCH3); MALDI-TOF (positive ion): m/z 649.22  
[M+Na]+ (Calcd 649.26). Anal. Calcd for C34H42O11 (626.69): C, 65.16; H, 6.76. Found: C, 
64.87; H, 6.70. 
 
3.4. Methyl (sodium β-D-glucopyranosyluronate)-(1→4)-2,3,6-tri-O-benzyl-α-D-
glucopyranoside (16) 
A stirred mixture of compound 15 (200 mg, 0.319 mmol) satd NaHCO3 solution (2.6 mL), 
KBr (20 mg, 0.16 mmol), and TEMPO (5 mg, 0.031 mmol) was cooled to 0 oC, and then 5% 
NaOCl solution (2.6 mL, ~1.75 mmol) was added slowly in portions. After 2 h the reaction 
mixture was extracted with CH2Cl2 (10 mL), and the aqueous phase was concentrated. Then 
MeOH (10 mL) was added and after stirring for 20 min, the insolubles were removed by 
filtration. The filtrate was concentrated under reduced pressure. The crude product was 
purified by silica gel chromatography in 85:15 CH2Cl2-MeOH, to give the uronic acid salt 16 
as a white powder (158 mg, 78%). [α]D +39.4 (c 0.13, MeOH); Rf 0.33 (85:15 CH2Cl2-
MeOH); 1H NMR (CD3OD, 360 MHz): δ (ppm) 7.46-7.21 (m, 15H, arom.), 4.51-3.60 (m, 
18H), 3.25 (s, 3H, OCH3); 13C NMR (CD3OD, 90 MHz): δ (ppm) 140.4, 139.6 139.5 (3 x Cq 
arom.), 129.4-128.4 (arom.), 104.2 (C-1’), 99.0 (C-1), 81.4, 81.1, 78.1, 77.6, 76.4, 75.4, 73.5, 
71.4 (skeleton carbons), 76.1, 74.4, 74.0 (3 x PhCH2), 69.9 (C-6), 55.5 (OCH3); MALDI-TOF 
(positive ion): m/z 685.39  [M+Na]+ (Calcd 685.22). Anal. Calcd for C34H39NaO12 (662.66): 
C, 61.63; H, 5.93. Found: C, 61.54; H, 6.01. 
 
  
3.5. Methyl (sodium 2,3,4-tri-O-methyl-β-D-glucopyranosyluronate)-(1→4)-2,3,6-tri-O-
benzyl-α-D-glucopyranoside (17) and methyl (sodium 4-deoxy-2,3-di-O-methyl-α-L-
threo-hex-4-enopyranosyluronate)-(1→4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside (18) 
To a solution of compound 16 (117 mg, 0.183 mmol) ) in DMF (2 mL) at 0 oC were 
successively added 60% NaH (44 mg, 1.1 mmol) and MeI (154 µL, 2.47 mmol). After 2 h 
stirring at this temperature, MeOH (0.5 mL) was added. The reaction mixture was stirred 15 
min, and the solvents were evaporated. The reaction gave a mixture of 17 and 18 which were 
separated by silica gel chromatography (1:1 n-hexane-acetone). Compound 17 (53 mg, 42%): 
[α]D +7.0 (c 0.13, CHCl3); Rf 0.59 (1:1 n-hexane-acetone); 1H NMR (CDCl3, 360 MHz): δ 
(ppm) 7.40-7.20 (m, 15H, arom.), 4.97-4.41 (m, 7H), 2.28 (m, 1H, J1’,2’ 7.4 Hz, H-1’), 3.85-
3.65 (m, 5H), 3.53, 3.41, 3.31 (4 x s, 12H, 4 x OCH3), 3.56-3.33 (m, 2H), 3.01-2.80 (m, 3H); 
13C NMR (CDCl3, 90 MHz): δ (ppm) 138.3, 138.0, 137.7 (3 x Cq arom), 128.3-127.3 (arom.), 
102.0 (C-1’), 98.1 (C-1), 85.2, 83.2, 80.7, 79.8, 79.1, 76.4, 69.9 (skeleton carbons), 75.4, 73.4, 
73.2 (3 x PhCH2), 67.8 (C-6), 60.4, 60.3, 60.0, 55.1 (4 x OCH3); MALDI-TOF (positive ion): 
m/z 727.19  [M+Na]+ (Calcd 727.27). Anal. Calcd for C37H45NaO12 (704.74): C, 63.06; H, 
6.44. Found: C, 62.91; H, 6.33. Compound 17 was prepered also from 22 according to the 
method described for the synthesis of 16 in a yield of 64%.  
Compound 18 ( 50 mg, 40%): [α]D +42.8 (c 0.60, CHCl3); Rf 0.42 (1:1 n-hexane-acetone); 1H 
NMR (CDCl3, 360 MHz): δ (ppm) 7.32-7.29 (15H, arom.), 6.07 (d, 1H J3’,4’ 2.9 Hz, H-4’), 
4.9-4.85 (m, 3H), 4.81-4.42 (m, 5H), 3.94-3.81 (m, 4H), 3.78-3.51 (m, 3H), 3.45, 3.42, 3.37 
(3 x s, 9H, 3 x OCH3), 3.21 (t, 1H, J 6.6 Hz); 13C NMR (CDCl3, 90 MHz): δ (ppm) 161.9 
(CO), 140.6 (C-5’), 138.1, 138.0, 137.6 (3 x Cq arom.), 128.4-127.9 (arom.), 109.2 (C-4’), 
101.3 (C-1’), 98.2 (C-1), 79.6, 79.5, 79.0, 76.9, 76.6, 69.7 (skeleton carbons), 75.8, 73.5, 73.4 
(3 x PhCH2), 67.8 (C-6), 59.9, 56.9, 55.3 (3 x OCH3); MALDI-TOF (positive ion): m/z 695.33  
[M+Na]+ (Calcd 695.24). Anal. Calcd for C36H41NaO11 (672.69): C, 64.28; H, 6.14. Found: C, 
64.08; H, 6.09. 
 
3.6. Methyl (sodium 2,3,4-tri-O-methyl-β-D-glucopyranosyluronate)-(1→4)-α-D-
glucopyranoside (19) 
A mixture of compound 17 (196 mg, 0.287 mmol) and Pd/C (10%, 80 mg) in 96% EtOH-
AcOH (19:1, 15 mL) was stirred in an autoclave under H2 atmosphere (at 10 bar) for 12 h. 
The catalyst was filtered off through a pad of Celite and the filtrate was concentrated under 
reduced pressure to give 19 (111 mg, 94%) as a white powder. [α]D +58.6 (c 0.11, MeOH); Rf 
0.24 (1:1 CH2Cl2-MeOH); 1H NMR (CD3OD, 360 MHz): δ (ppm) 4.73 (d, 1H, J1,2 3.4 Hz, H-
1), 4.50 (d, 1H, J1’,2’ 7.1 Hz, H-1’), 3.93-3.68 (m, 5H), 3.61, 3.55, 3.52, 3.43 (4 x s, 12H, 4 x 
OCH3), 3.63-3.35 (m, 2H), 3.25-3.07 (m, 3H); 13C NMR (CD3OD, 90 MHz): δ (ppm) 176.6 
(CO), 104.2 (C-1’), 100.9 (C-1), 87.2, 84.3, 82.7, 80.6, 76.7, 73.3, 73.1, 72.3 (skeleton 
carbons), 61.2, 61.1, 60.8, 55.7 (4 x OCH3), 61.0 (C-6); MALDI-TOF (positive ion): m/z 
457.17 [M+Na]+ (Calcd 457.13). Anal. Calcd for C16H27NaO12 (434.37): C, 44.24; H, 6.27. 
Found: C, 44.30; H, 6.29. 
 
3.7. Methyl (sodium 2,3,4-tri-O-methyl-β-D-glucopyranosyluronate)-(1→4)-2,3,6-tri-O-
sodium-sulfonato-α-D-glucopyranoside (4) 
A solution of compound 19 (101 mg, 0.245 mmol) in DMF (3 mL) was treated with the 
SO3·pyridine complex (585 mg, 3.675 mmol) for 5 h at room temperature, then cold satd 
NaHCO3 solution was added in excess (pH > 7). The resulting mixture was concentrated in 
vacuo. Then MeOH (5 mL) was added and after stirring for 20 min the insolubles were 
removed by filtration. The filtrate was concentrated under reduced pressure. The crude 
product was purified by Sephadex LH 20 column chromatography in MeOH to give 4 (124 
  
mg, 70%) as a white powder. [α]D +37.9 (c 0.11, MeOH); Rf 0.34 (4:6 CH2Cl2-MeOH); 1H 
NMR (D2O, 500 MHz): δ (ppm) 5.17 (d, 1H, J1,2 3.4 Hz, H-1), 4.67-4.63 (m, 2H, H-1’, H-3), 
4.39-4.37 (m, 3H, H-2, H-6a,b), 4.09 (m, 1H, H-5), 4.03 (m, 1H, H-4), 3.70 (d, 1H, J4’5’ 10.0 
Hz, H-5’), 3.63, 3.61, 3.49, 3.48 (4 x s, 12H, 4 x OCH3), 3.45 (t, 1H, J 9.2 Hz, H-4’), 3.88 (m, 
1H, H-3’), 3.23 (t, 1H, J 8.8 Hz H-2’); 13C NMR (D2O, 125 MHz): δ (ppm) 175.7 (CO), 100.8 
(C-1’), 97.2 (C-1), 84.2 (C-3’), 82.2 (C-2’), 81.6 (C-4), 76.4 (C-5’), 76.2 (C-3), 75.0 (C-2), 
73.5 (C-4), 69.1 (C-5), 66.1 (C-6), 61.1, 60.6, 56.0 (4 x OCH3); MALDI-TOF (positive ion): 
m/z 763.14 [M+Na]+ (Calcd 762.95). Anal. Calcd for C16H24Na4O21S3 (740.50): C, 25.95; H, 
3.27; S, 12.99. Found: C, 25.84; H, 3.26; S, 12.84. 
 
3.8. Methyl (6-O-triphenylmethyl-β-D-glucopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-α-D-
glucopyranoside (20) 
To a solution of compound 15 (1.11 g, 1.77 mmol) in pyridine (18 mL) triphenylmethyl 
chloride (988 mg, 3.54 mmol) was added. The mixture was stirred for 24 h at room 
temperature. After completion of the reaction, the mixture was concentrated in vacuo. 
The crude product was purified by silica gel chromatography (75:25 CH2Cl2-acetone + 1% 
Et3N) to give 20 (1.27 g, 83%) as a colourless syrup. [α]D -8.4 (c 0.27, CHCl3); Rf 0.54 (75:25 
CH2Cl2-acetone); 1H NMR (CDCl3, 360 MHz): δ (ppm) 8.54-7.25 (m, 30H, arom.), 4.88-4.44 
(m, 8H), 4.05-3.57 (m, 4H), 3.55-3.39 (m, 7H), 3.32 (s, 3H, OCH3), 3.29-3.21 (m, 4H); 13C 
NMR (CDCl3, 90 MHz): δ (ppm) 149.5-123.6 (arom.), 102.8 (C-1’), 98.1 (C-1), 86.9 (Ph3C), 
80.5, 79.4, 76.4, 76.1, 74.3, 73.9, 71.8, 69.4 (skeleton carbons), 74.7, 73.5, 73.3 (3 x PhCH2), 
68.4, 63.8 (2 x C-6), 55.0 (OCH3); MALDI-TOF (positive ion): m/z 891.35 calcd for [M+Na]+ 
(Calcd 891.37). Anal. Calcd for C53H56O11 (869.01): C, 73.25; H, 6.50. Found: C, 73.15; H, 
6.38. 
 
3.9. Methyl (2,3,4-tri-O-methyl-6-O-triphenylmethyl-β-D-glucopyranosyl)-(1→4)-2,3,6-
tri-O-benzyl-α-D-glucopyranoside (21) 
Compound 20 (1.20 g, 1.38 mmol) was methylated according to the method described for the 
synthesis of 17. The crude product was purified by silica gel chromatography (65:35 n-
hexane-EtOAc + 1% Et3N) to give 21 (1.08 g, 86%) as a colourless syrup. [α]D +9.1 (c 0.16, 
CHCl3); Rf 0.42 (65:35 n-hexane-EtOAc); 1H NMR (CDCl3, 360 MHz): δ (ppm) 7.50-7.09 
(m, 30H, arom.), 5.03-4.47 (m, 8H), 4.34 (m, 1H), 4.01-3.92 (m, 2H), 3.78-3.70 (m, 4H), 
3.59, 3.45, 3.39, 3.23 (4 x s, 12H, 4 x OCH3), 3.55-3.26 (m, 3H), 2.99-2.84 (m, 2H); 13C 
NMR (CDCl3, 90 MHz): δ (ppm) 143.8-126.7 (arom.), 102.2 (C-1’), 98.3 (C-1), 86.1 (Ph3C), 
86.9, 84.4, 79.8, 79.5, 79.2, 75.6, 74.4, 70.0 (skeleton carbons), 74.6, 73.4, 73.2 (3 x PhCH2), 
68.6, 61.4 (2 x C-6), 60.6, 60.4, 60.2, 55.2 (4 x OCH3); MALDI-TOF (positive ion): m/z 
933.41 [M+Na]+ (Calcd 933.42). Anal. Calcd for C56H62O11 (911.08): C, 73.82; H, 6.86. 
Found: C, 73.69; H, 6.78. 
 
3.10. Methyl (2,3,4-tri-O-methyl-β-D-glucopyranosyl)-(1→4)-2,3,6-tri-O-benzyl-α-D-
glucopyranoside (22) 
A solution of compound 21 (1.00 g, 1.01 mmol) in AcOH (80%, 18 mL) was stirred for 2 h at 
50 oC. The mixture was then concentrated in vacuo. The crude product was purified by silica 
gel chromatography (9:1 CH2Cl2-acetone) to give 22 (716 mg, 98%) as a colourless syrup. 
[α]D +21.3 (c 0.15, CHCl3); Rf 0.42 (9:1 CH2Cl2-acetone); 1H NMR (CDCl3, 360 MHz): δ 
(ppm) 7.37-7.24 (m, 15H arom.), 4.97-4.45 (m, 7H), 4.23 (d, 1H, J1’2’ 7.5 Hz, H-1’), 3.91-
3.67 (m, 6H), 3.59, 3.50, 3.46, 3.38 (4 x s, 12H, 4 x OCH3), 3.58-3.26 (m, 3H), 2.98-2.95 (m, 
4H); 13C NMR (CDCl3, 90 MHz): δ (ppm) 139.2-126.9 (arom.), 102.4 (C-1’), 98.2 (C-1), 
86.3, 84.1, 79.9, 79.6, 78.8, 77.1, 74.6, 70.0 (skeleton carbons), 75.0, 73.4, 73.2 (3 x PhCH2), 
67.8 (C-6), 61.7 (C-6’), 60.5, 60.4, 60.1, 55.2 (4 x OCH3); ); MALDI-TOF (positive ion): m/z 
  
691.28 [M+Na]+ (Calcd 691.31). Anal. Calcd for C37H48O11 (668.77): C, 66.45; H, 7.23. 
Found: C, 66.36; H, 7.18. 
 
3.11. 1,5-Anhydro-3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-C-methyl-D-arabino-hex-1-
enitol (25) 
To a solution of compound 23 (366 mg, 1 mmol) in CH2Cl2 (10 mL) at 0 oC Et3SiH (1.91 mL, 
12.0 mmol) and BF3·Et2O (0.25 mL, 2.0 mmol) were added. The reaction mixture was stirred 
at room temperature for 4 hours. The mixture was diluted with CH2Cl2 (200 mL), washed 
with satd NaHCO3 (2 x 100 mL), dried and concentrated. The crude product was purified by 
silica gel chromatography (4:1 n-hexane-EtOAc) to give 140 mg (41%) of 25 as white 
needles. Mp: 110-112 oC; [α]D –1.0 (c 0.19, CHCl3); Rf 0.71 (97:3 CH2Cl2-EtOAc); 1H NMR 
(CDCl3, 200 MHz): δ (ppm) 7.54-7.20 (m, 10H, arom.), 6.17 (s, 1H, H-1), 5.62 (s, 1H, 
CHPh), 4.94-4.69 (dd, 2H, J 11.8 Hz, PhCH2), 4.36 (m, 1H, H6a), 4.24 (d, 1H, J3,4 7.3 Hz, H-
3), 4.06 (dd, 1H, J4,5 9.4 Hz, H-4), 3.86-3-80 (m, 2H, H-5, H-6b), 1.63 (s, 3H, 2-CH3); 13C 
NMR (CDCl3, 50 MHz): δ (ppm) 139.9 (C-1), 138.7, 137.4 (Cquat, arom), 128.9-125.9 
(arom.), 110.3 (C-2), 101.1 (CHPh), 81.1 (C-4), 75.9 (C-3), 68.6 (C-5), 73.3 (PhCH2), 68.5 
(C-6), 13.8 (2-CH3); MALDI-TOF (positive ion): m/z 361.42 [M+Na]+ (Calcd 361.14). Anal. 
Calcd for C21H22O4 (338.41): C, 74.54; H, 6.55. Found: C, 74.35; H, 6.46. 
 
3.12. Methyl 2,6-di-O-benzyl-3-deoxy-3-C-methylene-α-D-ribo-hexopyranoside (28)   
Compound 26 (1.0 g, 2.714 mmol) was converted to 28 by the method described for the 
synthesis of 25. The crude product was purified by silica gel chromatography (7:3 n-hexane-
EtOAc) to give 784 mg (78%) of 28 as a colourless syrup. [α]D +39.6 (c 0.27, CHCl3); Rf 0.30 
(7:3 n-hexane-EtOAc); 1H NMR (CDCl3, 360 MHz): δ (ppm) 7.36-7.24 (m, 10H, arom.), 
5.38, 5.32 (2 x s, 2H, CH2=), 4.77 (d, 1H, PhCH2), 4.71 (d, 1H, J1,2 3.6 Hz, H-1), 4.62-4.52 
(m, 3H, PhCH2), 4.07 (d, 1H, J4,5 8.9 Hz, H-4), 3.94 (d, 1H, H-2), 3.74, 3.67 (2 x dd, 2H, H-
6a,b), 3.58 (m, 1H, H-5), 3.38 (s, 3H, OCH3), 2.65 (s, 1H, OH); 13C NMR (CDCl3, 90 MHz): 
δ (ppm) 143.0 (C-3), 137.8-127.6 (arom.), 105.3 (CH2=), 98.5 (C-1), 76.3 (C-2), 72.3 (C-4), 
73.5, 71.9 (2 x PhCH2), 70.1 (C-6), 69.4 (C-5), 55.1 (OCH3); Anal. Calcd for C22H26O5 
(370.44): C, 71.33; H, 7.07. Found: C, 71.25; H, 7.05. 
 
3.13. Methyl 2,6-di-O-benzyl-3-deoxy-3-C-(triethylammonium sulfonatomethyl)-α-D-
glucopyranoside (27) 
To a solution of compound 28 (500 mg, 1.35 mmol) in aqueous EtOH (70%, 80 mL) NaHSO3 
(1.4 g, 13.5 mmol) and tert-butyl peroxybenzoate (128 µL, 0.675 mmol) were added and the 
mixture was heated under reflux for 4 hours. After cooling, triethylamine was added, the 
mixture was diluted with EtOH, the insolubles were removed by filtration and the filtrate was 
concentrated in vacuo. The crude product was purified by silica gel chromatography (90:9:1 
CH2Cl2-MeOH-Et3N) to give 553 mg (74%) of 279 as a colourless syrup. [α]D +50.1 (c 0.22, 
CHCl3), lit.9 +50.3. The 1H and 13C NMR data were agreement with those published.9  
 
3.14. Methyl (β-D-glucopyranosyl)-(1→4)-2,3-di-O-benzyl-6-deoxy-6-C-
(triethylammonium sulfonatomethyl)-α-D-glucopyranoside (33)9 
Monitoring the proton deuterium exchange the initial proton spectrum was recorded in 
DMSO, then D2O was added. 1H NMR (DMSO, 400 MHz): δ (ppm) 7.39-7.29 (m, 10H, 
arom.), 5.08 (d, 1H, J 4.5 Hz, 2’-OH; 0.4H intensity 16 scans after adding D2O), 4.94-4.89 
(m, 3H, 3’-OH, 4’-OH, PhCH2; 1.6H intensity 16 scans after adding D2O), 4.77 (d, 1H, J1,2 
3.1 Hz, H-1), 4.71 (d, 1H, PhCH2), 4.61 (s, 2H, PhCH2), 4.48 (d, 1H, J1’,2’ 7.5 Hz, H-1’), 4.41-
4.38 (m, 1H, 6’-OH, the signal disappeared 16 scans after adding D2O), 3.72 (t, 1H, H-4), 
3.61-3.46 (m, 3H), 3.43-3.35 (m, 4H), 3.29 (s, 3H, OCH3), 3.18-3.15 (m, 1H, H-2), 3.08-3.03 
  
(m, 6H, Et3N-CH2), 3.01-21.98 (m, 1H, H-2’), 2.68-2.52 (m, 3H), 2.32 (m, 1H, H-6a), 1.77 
(m, 1H, H-6b), 1.19 (m, 9H, Et3N-CH3); 13C NMR (D2O, 90 MHz): δ (ppm) 138.9, 138.6 (Cq 
arom.), 129.5-128.9 (arom.), 103.2 (C-1’), 98.2 (C-1), 80.8, 80.3, 80.0, 77.5, 76.9, 75.3, 71.2, 
69.9 (skeleton carbons), 76.6, 74.0 (2 x PhCH2), 62.3 (C-6’), 55.8 (OCH3), 48.3 (C-7), 47.6 
(NCH2), 27.3 (C-6), 9.2 (NCH3). 
 
3.15. Methyl 1,2,4-tri-O-acetyl-3-O-methyl-α,β-L-idopyranosyluronate (37) 
A solution of 36 (5.0 g, 19.065 mmol) in aqueous 90% trifluoroacetic acid (40 mL) was kept 
at room temperature for 15 min, evaporated to dryness, and the residue was coevaporated with 
H2O (2 x 10 mL). The obtained crude product was acetylated using pyridine (28 mL) and 
acetic anhydride (14 mL). After 24 h at room temperature, the mixture was concentrated 
under reduced pressure, and traces of pyridine and acetic anhydride were coevaporated three 
times with toluene. Column chromatography (1:1 n-hexane-EtOAc) gave 59 (2.39 g, 36% for 
2 steps, α:β ~ 1:10) as a colourless oil.  
α: Rf 0.38 (1:1 n-hexane-EtOAc); 1H NMR (CDCl3, 360 MHz): δ (ppm) 6.22 (s, 1H, H-1), 
5.18 (s, 1H), 4.89 (s, 1H), 4.87 (s, 1H), 3.80 (s, 3H, COOCH3), 3.63 (s, 1H, H-3), 3.54 (s, 3H, 
OCH3), 2.12, 2.09, 2.08 (3s, 9H, 3 x CH3); 13C NMR (CDCl3, 90 MHz): δ (ppm) 169.6, 169.2, 
168.4, 168.1 (4 x CO), 91.0 (C-1), 73.4, 67.5, 67.0, 65.3 (skeleton carbons), 58.4 (OCH3), 
52.5 (COOCH3), 20.8, 20.7, 20.6 (3 x CH3). Anal. Calcd for C14H20O10 (348.30): C, 48.28; H, 
5.79. Found: C, 48.19; H, 5.74.  
β: Rf  0.30 (1:1 n-hexane-EtOAc);  [α]D +22.3 (c 0.10, CHCl3); mp 123-124 oC. The 1H and 
13C NMR data have been published.9 Anal. Calcd for C14H20O10 (348.30): C, 48.28; H, 5.79. 
Found: C, 48.37; H, 5.77. 
 
3.16. Methyl 2,4-di-O-acetyl-3-O-methyl-α,β-L-idopyranosyluronate (38)  
To a solution of 37 (2.0 g, 5.742 mmol) in THF (50 mL) benzyl amine (2.51 mL, 22.97 
mmol) was added. The reaction mixture was stirred for 4 h and monitored by TLC. The 
reaction was poured into 1 M aq HCl (50 mL), and the aqueous phase was extracted with 
EtOAc (3 x 100 mL). The combined organic phases were dried, and evaporated to dryness. 
Column chromatography (85:15 CH2Cl2-acetone) gave 38 (1.39 g, 79%) as a colourless oil. 
[α]D +4.7 (c 0.10, CHCl3); Rf 0.43 (85:15 CH2Cl2-acetone); 1H NMR (CDCl3, 500 MHz): δ 
(ppm) 5.33 (s, 0.6H), 5.31 (s, 0.4H), 5.19 (s, 0.6H), 5.12 (s, 0.4H), 5.10 (s, 0.6H), 4.99 (s, 
0.6H), 4.88 (s, 0.4H), 4.82 (s, 0.6H), 4.62 (s, 0.8H), 3.78, 3.77, 3.60, 3.55 (4 x s, 6H, 4 x 
OCH3), 3.45, 3.44 (2 x s, 1H), 2.08, 2.06, 2.04 (3 x s, 6H, 4 x CH3); 13C NMR (CDCl3, 125 
MHz): δ (ppm) 92.6, 91.7 (C-1α, C-1β), 74.8, 74.2, 72.2, 67.4, 66.6, 66.5, 65.3 (skeleton 
carbons), 58.9, 58.6 (2 x OCH3), 52.4, 52.3 (2 x COOCH3), 20.6, 20.5, 20.4, 20.3 (4 x CH3); 
Anal. Calcd for C12H18O9 (306.27): C, 47.06; H, 5.92. Found: C, 46.93; H, 5.98  
 
3.17. Methyl (methyl 2,4-di-O-acetyl-3-O-methyl-α-L-idopyranosyluronate)-(1→4)-2,3,6-
tri-O-benzyl-α-D-glucopyranoside (40) 
A mixture of compound 13 (400 mg, 0.861 mmol), imidate 39 (582 mg, 1.292 mmol) and 4 Å 
molecular sieves in dry CH2Cl2 (8 mL) was stirred for 15 min at room temperature, then 
cooled to -20 oC under argon. TMSOTf (0.1 M in CH2Cl2, 1.29 mL, 0.13 mmol) was added, 
and the reaction mixture was allowed to warm up to 0 oC in 30 min. After completion of the 
reaction it was quenched by addition of Et3N (0.2 mL). The reaction mixture was then filtered 
and concentrated. The crude product was purified by silica gel chromatography (7:3 n-
hexane-acetone) to give 40 as a colourless oil (609 mg, 94%). [α]D -25.1 (c 0.15, CHCl3); Rf 
0.48 (1:1 n-hexane-EtOAc); 1H NMR (CDCl3, 360 MHz): δ (ppm) 7.35-7.26 (m, 15H, arom.), 
5.11-4.98 (m, 4H), 4.79-4.49 (m, 7H), 3.99-3.71 (m, 6H), 3.63-3.58 (m, 1H), 3.52, 3.36, 3.33 
(3 x s, 9H, 3 x OCH3), 2.00, 1.99 (2 x s, 6H, 2 x CH3); 13C NMR (CDCl3, 90 MHz): δ (ppm) 
  
169.8, 169.5, 168.5 (3 x CO), 138.6, 137.9, 137.8 (3 x Cq arom.), 128.2-126.9 (arom.), 97.8, 
96.8 (2 x C-1), 80.0, 79.5, 74.2, 73.9, 69.9, 67.1, 66.7, 65.8 (skeleton carbons), 74.8, 73.2, 
73.0 (3 x PhCH2), 68.0 (C-6), 58.2, 55.0, 51.8 (3 x OCH3), 20,7, 20.6 (2 x CH3); MALDI-
TOF (positive ion): m/z 775.39 [M+Na]+ (Calcd 775.29). Anal. Calcd for C40H48O14 (752.80): 
C, 63.82; H, 6.43. Found: C, 63.68; H, 6.46. 
 
3.18. Methyl (methyl 3-O-methyl-α-L-idopyranosyluronate)-(1→4)-2,3,6-tri-O-benzyl-α-
D-glucopyranoside (41) 
Compound 40 (88 mg, 0.117 mmol) was deacetylated as described for the synthesis of 15. 
The crude product was purified by silica gel chromatography (85:15 CH2Cl2-acetone) to give 
41 as a colourless oil (74 mg, 95%). [α]D -17.3 (c 0.15, CHCl3); Rf 0.50 (85:15 CH2Cl2-
acetone); 1H NMR (CDCl3, 360 MHz): δ (ppm) 7.33-7.25 (m, 15H, arom.), 5.03 (s, 1H), 4.93-
4.51 (m, 8H), 3.92-3.71 (m, 5H), 3.68-3.54 (m, 5H), 3.47-3.44 (m, 1H), 3.40, 3.33 (2 x s, 9H, 
3 x OCH3), 13C NMR (CDCl3, 90 MHz): δ (ppm) 170.5 (CO), 138.7, 137.8. 137.5 (3 x Cq 
arom.), 128.2-126.8 (arom.), 100.1, 97.7 (2 x C-1), 79.9, 79.6, 77.5, 74.6, 69.8, 68.3, 67.5, 
66.8 (skeleton carbons), 74.7, 73.3, 73.2 (3 x PhCH2), 68.5 (C-6), 57.8, 54.9, 51.7 (3 x 
OCH3); MALDI-TOF (positive ion): m/z 691.35 [M+Na]+ (Calcd 691.27). Anal. Calcd for 
C36H44O12 (668.73): C, 64.66; H, 6.63. Found: C, 64.59; H, 6.61. 
 
3.19. Methyl (methyl 2,3,4-tri-O-methyl-α-L-idopyranosyluronate)-(1→4)-2,3,6-tri-O-
benzyl-α-D-glucopyranoside (42) 
To a solution of 41 (134 mg, 0.200 mmol) in DMF (4.5 mL) at rt were successively added 
freshly prepared Ag2O (370 mg, 1.6 mmol, 4 equiv/OH) and MeI (37 µL, 0.6 mmol, 1.5 
equiv/OH). After 96 h stirring at this temperature, diluted with CH2Cl2, filtered off through a 
pad of Celite and the filtrate was concentrated under reduced pressure. The crude product was 
purified by silica gel chromatography (95:5 CH2Cl2-acetone) to give 42 as a colourless syrup 
(105 mg, 76%). [α]D -19.6 (c 0.10, CHCl3); Rf 0.49 (95:5 CH2Cl2-acetone); 1H NMR (CDCl3, 
360 MHz): δ (ppm) 7.39-7.27 (m, 15H, arom.), 5.17 (d, 1H, J 5.3 Hz), 4.87 (dd, 2H, PhCH2), 
4.75-4.55 (m, 6H), 3.91-3.56 (m, 7H), 3.53, 3.48, 3.42, 3.41, 3.36 (5 x s, 15H, 5 x OCH3), 
3.35-3.30 (m, 1H), 3.04-2.98 (m, 1H); 13C NMR (CDCl3, 90 MHz): δ (ppm) 169.5 (CO), 
139.0, 138.1, 137.9 (3 x Cq arom.), 128.2-127.0 (arom.), 99.6, 98.0 (2 x C-1), 81.3, 79.9, 79.6, 
79.5, 78.8, 75.8, 70.7, 70.1 (skeleton carbons), 75.1, 73.4, 73.3 (3 x PhCH2), 68.2 (C-6), 59.7, 
59.5, 58.8, 55.1, 51.5 (5 x OCH3); MALDI-TOF (positive ion): m/z 719.35 [M+Na]+ (Calcd 
719.30). Anal. Calcd for C38H48O12 (696.78): C, 65.50; H, 6.94. Found: C, 65.64; H, 6.97. 
 
3.20. Methyl (sodium 2,3,4-tri-O-methyl-α-L-idopyranosyluronate)-(1→4)-(2,3,6-tri-O-
benzyl-α-D-glucopyranoside (43) 
Compound 42 (184 mg, 0.260 mmol) was dissolved in MeOH (20 mL) and treated with 0.1M 
aq NaOH solution (20 mL). After 24 h stirring at rt the TLC showed complete conversion of 
the carboxylic ester into sodium salt. The mixture was neutralized with acetic acid, 
concentrated in vacuo and the residue was purified by silica gel chromatography (95:5 
CH2Cl2-MeOH) to give 43 as a colourless syrup (126 mg, 68%), [α]D +23.1 (c 0.19, MeOH); 
Rf 0.25 (9:1 CH2Cl2-MeOH); 1H NMR (CD3OD, 360 MHz): δ (ppm) 7.34-7.25 (m, 15H, 
arom.), 5.17 (d, 1H, J 4.0 Hz), 4.88 (s, 1H), 4.73-4.50 (m, 7H), 3.81-3.70 (m, 5H), 3.58-3.53 
(m, 2H), 3.47-3.44 (m, 1H), 3.48, 3.39, 3.36, 3.32 (4 x s, 12H, 4 x OCH3), 3.15-3.11 (m, 1H); 
13C NMR (CD3OD, 90 MHz): δ (ppm) 174.0 (CO), 140.1, 139.5, 139.4 (3 x Cq arom.), 129.3-
128.3 (arom.), 100.7, 98.8 (2 x C-1), 81.3, 80.9, 81.0, 80.9, 79.7, 79.1, 77.1, 71.7 (skeleton 
carbons), 76.2, 74.4, 73.9 (3 x PhCH2), 69.8 (C-6), 59.7, 59.3, 59.0, 55.5 (4 x OCH3); 
MALDI-TOF (positive ion): m/z 705.42 (uronic acid) [M+Na]+ (Calcd 705.29). Anal. Calcd 
for C37H45NaO12 (704.74): C, 63.06; H, 6.44. Found: C, 63.07; H, 6.40. 
  
 
3.21. Methyl (sodium 2,3,4-tri-O-methyl-α-L-idopyranosyluronate)-(1→4)-α-D-
glucopyranoside (44) 
Compound 43 (110 mg, 0.156 mmol) was debenzylated according to the method described for 
the synthesis of 19. The crude product was purified by silica gel chromatography (1:1 
CH2Cl2-MeOH) to give 44 as a white powder (58 mg, 85%). [α]D +54.0 (c 0.10, MeOH); Rf 
0.21 (1:1 CH2Cl2-MeOH); 1H NMR (D2O, 360 MHz): δ (ppm) 5.06 (s, 1H), 4.80 (s, 1H), 4.65 
(s, 1H), 3.88-3.85 (m, 1H), 3.81-3.56 (m, 8H), 3.52, 3.49, 3.42, 3.40 (4 x s, 12H, 4 x OCH3); 
13C NMR (D2O, 90 MHz): δ (ppm) 175.9 (CO), 99.3, 99.0 (2 x C-1), 77.4, 77.2, 76.9, 75.9, 
71.7, 71.4, 70.5, 69.6 (skeleton carbons), 60.1 (C-6), 58.3, 57.9, 54.9 (4 x OCH3); MALDI-
TOF (positive ion): m/z 457.32 (sodium salt) [M+Na]+ (Calcd 457.13). Anal. Calcd for 
C16H27NaO12 (434.37): C, 44.24; H, 6.27. Found: C, 44.31; H, 6.30. 
 
3.22. Methyl (sodium 2,3,4-tri-O-methyl-α-L-idopyranosyluronate)-(1→4)-2,3,6-tri-O-
(sodium sulfonato)-α-D-glucopyranoside (8) 
Compound 44 (50 mg, 0.115 mmol) was O-sulfated according to the method described for the 
synthesis of 4. The crude product was purified by Sephadex LH-20 column chromatography 
eluted with H2O to give 8 as a white powder (80 mg, 94%). [α]D +36.8 (c 0.15, MeOH); Rf 
0.10 (8:5:1 CH2Cl2-MeOH-H2O); 1H NMR (D2O, 500 MHz): δ (ppm) 5.19 (d,1H, J1,2 3.5 Hz, 
H-1), 5.06 (d, 1H, J1’,2’ 3.3 Hz, H-1’), 4.82 (d, 1H, J4’,5’ 2.7 Hz, H-5’), 4.67 (t, 1H, J 9.4 Hz, 
H-3), 4.43 (m, 1H, H-6a), 4.41 (m, 1H, H-2), 4.32 (m, 1H, H-6b), 4.12 (m, 1H, H-5), 4.03 (t, 
1H, J 9.7 Hz, H-4), 3.82 (m, 1H, H-4’), 3.67 (m, 1H, H-3’), 3.58, 3.57, 3.51, 3.48 (4 x s, 12H, 
4 x OCH3), 3.50 (m, 1H, H-2); 13C NMR (D2O, 125 MHz) δ (ppm) 99.6 (C-1’), 97-2 (C-1), 
79.0 (C-4’), 78.1 (C-3’), 78.0 (C-2’), 76.1 (C-3), 75.3 (C-2), 73.3 (C-4), 70.9 (C-5’), 68.8 (C-
5), 66.3 (C-6), 58.8, 58.4, 58.0, 55.3 (4 x OCH3); MALDI-TOF (positive ion): m/z 763.03 
(tetrasodium salt) [M+Na]+ (Calcd 762.95). Anal. Calcd for C16H24Na4O21S3 (740.50): C, 
25.95; H, 3.27; S, 12.99. Found: C, 25.76; H, 3.22; S, 12.89. 
 
3.23. Methyl (methyl 2,3,4-tri-O-methyl-α-L-idopyranosyluronate)-(1→4)-3,6-di-O-
benzyl-2-deoxy-2-C-(sodium sulfonatomethyl)-α-D-glucopyranoside (47); and methyl 
(methyl 4-deoxy-2,3-di-O-methyl-α-L-threo-hex-4-enopyranosyluronate)-(1→4)-3,6-di-O-
benzyl-2-deoxy-2-C-(sodium sulfonatomethyl)-α-D-glucopyranoside (48)  
Compound 46 (190 mg, 0.28 mmol) was methylated according to the method described for 
the synthesis of  17 to give a mixture of 47 and 48 (140 mg) which could not be separated by 
silica gel chromatography. Rf of the mixture: 0.71 (7:3 CH2Cl2-MeOH), 0.22 (n-hexane-
EtOAc).  
Compound 47: 13C NMR (CDCl3, 125 MHz): δ (ppm) 169.9 (CO), 138.3-127. (arom.), 99.8, 
98.7 (C-1, C-1’), 82.2, 80.3, 79.2, 77.4, 76.5, 71.2, 70.6 (skeleton carbons), 73.2 (2 x PhCH2) 
68.3 (C-6), 60.0, 59.7, 58.8, 55.2, 51.8 (5 x OCH3), 48.1 (CH2SO3-), 42.4 (C-2); MALDI-TOF 
(positive ion): m/z 729.31 [M+Na]+ (Calcd 729.25). 
For NMR measurments 35 mg of the mixture of 47 and 48  in DMF (1 mL) was treated with 
NaH (5 mg) to give 48 as a colourless oil; 1H NMR (CDCl3, 500 MHz); δ (ppm) 7.32-7.15 
(m, 10H, arom.), 5.95 (d, 1H, J3’,4’ 3.0 Hz, H-4’), 5.17 (s, 1H), 4.90-4.41 (m, 5H), 4.07 (t, 1H, 
J 9.5 Hz), 3.81-3.57 (m, 4H), 3.48, 3.44, 3.41, 3.20 (4 x s, 12H, 4 x OCH3), 3.23-3.20 (m, 
1H), 3.06-2.90 (m, 3H), 2.53 (m, 1H, H-2); 13C NMR (CDCl3, 125 MHz): δ (ppm) 162.5 
(CO), 141.8 (C-5’), 138.1, 137.9 (2 x Cq arom.), 128.1-127.6 (arom.), 109.0 (C-4’), 101.4, 
99.0 (C-1, C-1’), 79.3, 78.6, 76.6, 70.4 (skeleton carbons), 73.2 (2 x PhCH2), 68.1 (C-6), 59.9, 
57.0, 55.3, 52.5 (4 x OCH3), 47.7 (CH2SO3-), 42.3 (C-2); MALDI-TOF (positive ion): m/z 
697.31 [M+Na]+ (Calcd 697.21).  
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